Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated <i>KRAS</i> p.G12C-mutated NSCLC. (Fund...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 1,567
- Institution
- University Hospital of Zurich
External Links
Identifiers
- ORCID
- 0000-0002-5778-5270
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.